Document is current
Any future updates will be listed below
-
Authors
Tavris, Bengi S.
Morath, Christian
Rupp, Christoph
Szudarek, Roman
Uhle, Florian
Sweeney, Timothy E.
Liesenfeld, Oliver
Fiedler-Kalenka, Mascha O.
Dubler, Simon
Zeier, Martin
Schmitt, Felix C. F.
Weigand, Markus A.
Brenner, Thorsten
Nusshag, Christian
-
Funding
Funding for this research was provided by:
Medizinischen Fakultät Heidelberg, Universität Heidelberg
Universitätsklinikum Heidelberg
Universitätsklinikum Heidelberg
- License Information
-
More Information
Article History
Received: 7 January 2025
Accepted: 7 March 2025
First Online: 26 March 2025
Declarations
:
: The study design was approved by the local Ethics Committee of the Medical Faculty of Heidelberg (S-200/2017) and registered at the German Clinical Trials Register (DRKS-ID: DRKS00012446). Written informed consent was obtained from all participants or their legal representatives.
: Not applicable.
: Christian Nusshag received travel expense reimbursements from SphingoTec. Florian Uhle is an employee and stock option holder of Sphingotec and Inflammatix. Oliver Liesenfeld is stock option holder of Inflammatix. Tim Sweeney is an employee and stock option holder of Inflammatix. All other authors of this manuscript have no conflicts of interest to disclose as described by the journal.
